Alternative polyadenylation is associated with lower expression of PABPN1 and poor prognosis in non-small cell lung cancer

Cancer Science

Volumn 105, Issue 9, 2014, Pages 1135-1141

  Ichinose, Junji ^a   Watanabe, Kousuke ^a   Sano, Atsushi ^a   Nagase, Takahide ^a   Nakajima, Jun ^a   Fukayama, Masashi ^a   Yatomi, Yutaka ^a   Ohishi, Nobuya ^a   Takai, Daiya ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

Alternative polyadenylation; Lung cancer; PABPN1; Prognosis; Rmodel

Indexed keywords

3' UNTRANSLATED REGION; AGED; ALTERNATIVE POLYADENYLATION; ARTICLE; C1ORF52 GENE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; DIEXF GENE; E2F1 GENE; ESYT2 GENE; FEMALE; FOLLOW UP; GENE EXPRESSION; HN1L GENE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MCM2 GENE; MKI67 GENE; MUC20 GENE; NDFIP2 GENE; NON SMALL CELL LUNG CANCER; PABPN1 GENE; PHENOTYPE; POLYADENYLATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RBM33 GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCAMP1 GENE; SMC1A GENE; SQUAMOUS CELL LUNG CARCINOMA; SSR1 GENE; TOP2A GENE; TUMOR GENE; ADENOCARCINOMA; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; MORTALITY; PABPN1; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; RMODEL; RNA INTERFERENCE;

MICRORNA; PABPN1 PROTEIN, HUMAN; POLYADENYLIC ACID BINDING PROTEIN;

ALTERNATIVE POLYADENYLATION; LUNG CANCER; PABPN1; PROGNOSIS; RMODEL;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MICRORNAS; POLY(A)-BINDING PROTEIN I; POLYADENYLATION; PROGNOSIS; RNA INTERFERENCE;

EID: 84910015522     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12472     Document Type: Article

References (38)

1. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-33.
2. Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524-9.
3. Takamizawa J, Konishi H, Yanagisawa K et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64: 3753-6.
4. Hayashita Y, Osada H, Tatematsu Y et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005; 65: 9628-32.
5. Yanaihara N, Caplen N, Bowman E et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9: 189-98.
6. Watanabe K, Takai D. Disruption of the expression and function of microRNAs in lung cancer as a result of epigenetic changes. Front Genet 2013; 4: 275.
7. Merritt WM, Lin YG, Han LY et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 2008; 359: 2641-50.
8. Kumar MS, Pester RE, Chen CY et al. Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev 2009; 23: 2700-4.
9. Martello G, Rosato A, Ferrari F et al. A MicroRNA targeting dicer for metastasis control. Cell 2010; 141: 1195-207.
10. Melo SA, Ropero S, Moutinho C et al. A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet 2009; 41: 365-70.
11. Karube Y, Tanaka H, Osada H et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci 2005; 96: 111-5.
12. Kitano K, Watanabe K, Emoto N et al. CpG island methylation of microRNAs is associated with tumor size and recurrence of non-small-cell lung cancer. Cancer Sci 2011; 102: 2126-31.
13. Watanabe K, Emoto N, Hamano E et al. Genome structure-based screening identified epigenetically silenced microRNA associated with invasiveness in non-small-cell lung cancer. Int J Cancer 2012; 130: 2580-90.
14. Tian B, Hu J, Zhang H, Lutz CS. A large-scale analysis of mRNA polyadenylation of human and mouse genes. Nucleic Acids Res 2005; 33: 201-12.
15. Ozsolak F, Kapranov P, Foissac S et al. Comprehensive polyadenylation site maps in yeast and human reveal pervasive alternative polyadenylation. Cell 2010; 143: 1018-29.
16. Shepard PJ, Choi EA, Lu J, Flanagan LA, Hertel KJ, Shi Y. Complex and dynamic landscape of RNA polyadenylation revealed by PAS-Seq. RNA 2011; 17: 761-72.
17. Moore MJ. From birth to death: the complex lives of eukaryotic mRNAs. Science 2005; 309: 1514-8.
18. Sandberg R, Neilson JR, Sarma A, Sharp PA, Burge CB. Proliferating cells express mRNAs with shortened 3′ untranslated regions and fewer microRNA target sites. Science 2008; 320: 1643-7.
19. Ji Z, Lee JY, Pan Z, Jiang B, Tian B. Progressive lengthening of 3′ untranslated regions of mRNAs by alternative polyadenylation during mouse embryonic development. Proc Natl Acad Sci USA 2009; 106: 7028-33.
20. Thomsen S, Azzam G, Kaschula R, Williams LS, Alonso CR. Developmental RNA processing of 3'UTRs in Hox mRNAs as a context-dependent mechanism modulating visibility to microRNAs. Development 2010; 137: 2951-60.
21. Ji Z, Tian B. Reprogramming of 3′ untranslated regions of mRNAs by alternative polyadenylation in generation of pluripotent stem cells from different cell types. PLoS ONE 2009; 4: e8419.
22. Mayr C, Bartel DP. Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell 2009; 138: 673-84.
23. Fu Y, Sun Y, Li Y et al. Differential genome-wide profiling of tandem 3′ UTRs among human breast cancer and normal cells by high-throughput sequencing. Genome Res 2011; 21: 741-7.
24. Elkon R, Drost J, van Haaften G et al. E2F mediates enhanced alternative polyadenylation in proliferation. Genome Biol 2012; 13: R59.
25. Bava FA, Eliscovich C, Ferreira PG et al. CPEB1 coordinates alternative 3′-UTR formation with translational regulation. Nature 2013; 495: 121-5.
26. Jenal M, Elkon R, Loayza-Puch F et al. The poly(A)-binding protein nuclear 1 suppresses alternative cleavage and polyadenylation sites. Cell 2012; 149: 538-53.
27. Elias JM. Cell proliferation indexes: a biomarker in solid tumors. Biotech Histochem 1997; 72: 78-85.
28. Oda M, Arakawa Y, Kano H et al. Quantitative analysis of topoisomerase IIalpha to rapidly evaluate cell proliferation in brain tumors. Biochem Biophys Res Commun 2005; 331: 971-6.
29. Torres-Rendon A, Roy S, Craig GT, Speight PM. Expression of Mcm2, geminin and Ki67 in normal oral mucosa, oral epithelial dysplasias and their corresponding squamous-cell carcinomas. Br J Cancer 2009; 100: 1128-34.
30. Giaginis C, Vgenopoulou S, Vielh P, Theocharis S. MCM proteins as diagnostic and prognostic tumor markers in the clinical setting. Histol Histopathol 2010; 25: 351-70.
31. Jakobsen JN, Sorensen JB. Clinical impact of ki-67 labeling index in non-small cell lung cancer. Lung Cancer 2013; 79: 1-7.
32. Sobin LH, Gospodarowicz MK, Wittekind C. International Union Against Cancer (UICC) TNM Classification of Malignant Tumours, 7th edn. New York: Wiley-Liss, 2010.
33. Salisbury J, Hutchison KW, Wigglesworth K, Eppig JJ, Graber JH. Probe-level analysis of expression microarrays characterizes isoform-specific degradation during mouse oocyte maturation. PLoS ONE 2009; 4: e7479.
34. Kuner R, Muley T, Meister M et al. Global gene expression analysis reveals specific patterns of cell junctions in non-small cell lung cancer subtypes. Lung Cancer 2009; 63: 32-8.
35. Crouser ED, Julian MW, Crawford M et al. Differential expression of microRNA and predicted targets in pulmonary sarcoidosis. Biochem Biophys Res Commun 2012; 417: 886-91.
36. Lembo A, Di Cunto F, Provero P. Shortening of 3′UTRs correlates with poor prognosis in breast and lung cancer. PLoS ONE 2012; 7: e31129.
37. Morris AR, Bos A, Diosdado B et al. Alternative cleavage and polyadenylation during colorectal cancer development. Clin Cancer Res 2012; 18: 5256-66.
38. Singh P, Alley TL, Wright SM et al. Global changes in processing of mRNA 3′ untranslated regions characterize clinically distinct cancer subtypes. Cancer Res 2009; 69: 9422-30.